{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:02:40Z","timestamp":1768316560733,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education","award":["NRF- 2019R1A2C1088904"],"award-info":[{"award-number":["NRF- 2019R1A2C1088904"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Self-sealing hyaluronic acid (HA)-coated self-sealing 30-gauge needles exhibiting instant leakage prevention of intravitreal humor and injected drug were developed in this study. Ninety New Zealand rabbits were used in this study. We assessed dye regurgitation in intravitreal ICG dye injections using HA-coated needles (HA needle group) and conventional needles (control group). Vitreous humor levels of anti-vascular endothelial growth factor (VEGF) were compared between groups one, three, and seven days after intravitreal bevacizumab (0.016\u00a0mL) injections. Expression levels of inflammatory cytokines in the aqueous humor and vitreous humor, including prostaglandin E<jats:sub>2<\/jats:sub> (PGE<jats:sub>2<\/jats:sub>), interferon-\u03b3, tumor necrosis factor-\u03b1, interleukin (IL)-1\u03b2, IL-4, IL-6, IL-17, and IL-8, were compared between HA needle, control, and normal (in which intravitreal injection was not performed) groups following 12 intravitreal injections over a period of one week. In the HA needle group, HA remained at the injection site and blocked the hole after intravitreal injection. Dye regurgitation occurred significantly less frequently in the HA needle group (16.7%) than the control group (55.6%) after intravitreal ICG dye injection. Meanwhile, vitreous anti-VEGF levels were markedly higher in the HA needle group than the control group one and three days after intravitreal bevacizumab injections. After 12 intravitreal injections, expression levels of aqueous and vitreous IL-8 significantly increased in the control group compared to the HA needle and normal groups. Conversely, there were no significant differences in the expression of the other seven cytokines among the three groups. Intravitreal injections using HA-coated self-sealing 30-gauge needles can block the outflow of vitreous humor and drugs through the needle passage.<\/jats:p>","DOI":"10.1038\/s41598-021-96561-8","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:02:51Z","timestamp":1629453771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Self-sealing hyaluronic acid-coated 30-gauge intravitreal injection needles for preventing vitreous and drug reflux through needle passage"],"prefix":"10.1038","volume":"11","author":[{"given":"Youngsub","family":"Eom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soomi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungah","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Young","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Young","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boram","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Sue","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haeshin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Myung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Suk","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"96561_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski, A. et al. 2018 update on intravitreal injections: Euretina expert consensus recommendations. Ophthalmologica 239, 181\u2013193. https:\/\/doi.org\/10.1159\/000486145 (2018).","journal-title":"Ophthalmologica"},{"key":"96561_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100862","volume":"80","author":"GB Melo","year":"2021","unstructured":"Melo, G. B. et al. Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections. Prog. Retin. Eye Res. 80, 100862. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100862 (2021).","journal-title":"Prog. Retin. Eye Res."},{"key":"96561_CR3","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","volume":"117","author":"OP Gupta","year":"2010","unstructured":"Gupta, O. P. et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 117, 2134\u20132140. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.032 (2010).","journal-title":"Ophthalmology"},{"key":"96561_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ajo.2011.05.008","volume":"152","author":"S Day","year":"2011","unstructured":"Day, S., Acquah, K., Lee, P. P., Mruthyunjaya, P. & Sloan, F. A. Medicare costs for neovascular age-related macular degeneration, 1994\u20132007. Am. J. Ophthalmol. 152, 1014\u20131020. https:\/\/doi.org\/10.1016\/j.ajo.2011.05.008 (2011).","journal-title":"Am. J. Ophthalmol."},{"key":"96561_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133628","volume":"10","author":"H Tamura","year":"2015","unstructured":"Tamura, H. et al. The clinical effectiveness and cost-effectiveness of screening for age-related macular degeneration in Japan: A Markov modeling study. PLoS ONE 10, e0133628. https:\/\/doi.org\/10.1371\/journal.pone.0133628 (2015).","journal-title":"PLoS ONE"},{"key":"96561_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19740","volume":"19","author":"PH Scanlon","year":"2015","unstructured":"Scanlon, P. H. et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess 19, 1\u2013116. https:\/\/doi.org\/10.3310\/hta19740 (2015).","journal-title":"Health Technol Assess"},{"key":"96561_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/aos.13233","volume":"95","author":"A Rasmussen","year":"2017","unstructured":"Rasmussen, A. et al. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: Visual outcome and number of injections. Acta Ophthalmol. 95, 128\u2013132. https:\/\/doi.org\/10.1111\/aos.13233 (2017).","journal-title":"Acta Ophthalmol."},{"key":"96561_CR8","doi-asserted-by":"publisher","first-page":"6988","DOI":"10.1039\/D0PY00919A","volume":"11","author":"DD Nguyen","year":"2020","unstructured":"Nguyen, D. D. & Lai, J.-Y. Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment. Polym. Chem. 11, 6988\u20137008 (2020).","journal-title":"Polym. Chem."},{"key":"96561_CR9","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri, S. J. et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114, 2179\u20132182. https:\/\/doi.org\/10.1016\/j.ophtha.2007.09.012 (2007).","journal-title":"Ophthalmology"},{"key":"96561_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ajo.2004.01.028","volume":"137","author":"SD Chen","year":"2004","unstructured":"Chen, S. D., Mohammed, Q., Bowling, B. & Patel, C. K. Vitreous wick syndrome\u2014a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana. Am. J. Ophthalmol. 137, 1159\u20131160. https:\/\/doi.org\/10.1016\/j.ajo.2004.01.028 (2004).","journal-title":"Am. J. Ophthalmol."},{"key":"96561_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10792-016-0241-4","volume":"37","author":"Y Xu","year":"2017","unstructured":"Xu, Y. & Tan, C. S. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int. Ophthalmol. 37, 325\u2013332. https:\/\/doi.org\/10.1007\/s10792-016-0241-4 (2017).","journal-title":"Int. Ophthalmol."},{"key":"96561_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09286586.2015.1090004","volume":"23","author":"EH Souied","year":"2016","unstructured":"Souied, E. H. et al. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: A retrospective claims database analysis. Ophthalm. Epidemiol. 23, 71\u201379. https:\/\/doi.org\/10.3109\/09286586.2015.1090004 (2016).","journal-title":"Ophthalm. Epidemiol."},{"key":"96561_CR13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3928\/23258160-20151027-07","volume":"46","author":"SJ Garg","year":"2015","unstructured":"Garg, S. J., Dollin, M., Hsu, J., Storey, P. & Vander, J. F. Effect of a strict \u201cno-talking\u201d policy during intravitreal injection on post-injection endophthalmitis. Ophthalm. Surg. Lasers Imaging Retina 46, 1028\u20131034. https:\/\/doi.org\/10.3928\/23258160-20151027-07 (2015).","journal-title":"Ophthalm. Surg. Lasers Imaging Retina"},{"key":"96561_CR14","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/bjophthalmol-2015-307707","volume":"100","author":"N Rayess","year":"2016","unstructured":"Rayess, N. et al. Incidence and clinical features of post-injection endophthalmitis according to diagnosis. Br. J. Ophthalmol. 100, 1058\u20131061. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307707 (2016).","journal-title":"Br. J. Ophthalmol."},{"key":"96561_CR15","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","volume":"122","author":"BL VanderBeek","year":"2015","unstructured":"VanderBeek, B. L., Bonaffini, S. G. & Ma, L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology 122, 2311-2315.e2311. https:\/\/doi.org\/10.1016\/j.ophtha.2015.07.005 (2015).","journal-title":"Ophthalmology"},{"key":"96561_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaophthalmol.2015.2556","volume":"133","author":"BL VanderBeek","year":"2015","unstructured":"VanderBeek, B. L., Bonaffini, S. G. & Ma, L. Association of compounded bevacizumab with postinjection endophthalmitis. JAMA Ophthalmol. 133, 1159\u20131164. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.2556 (2015).","journal-title":"JAMA Ophthalmol."},{"key":"96561_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40942-015-0010-y","volume":"1","author":"R Merani","year":"2015","unstructured":"Merani, R. & Hunyor, A. P. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: A comprehensive review. Int. J. Retina Vitreous 1, 9. https:\/\/doi.org\/10.1186\/s40942-015-0010-y (2015).","journal-title":"Int. J. Retina Vitreous"},{"key":"96561_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nmat4758","volume":"16","author":"M Shin","year":"2017","unstructured":"Shin, M. et al. Complete prevention of blood loss with self-sealing haemostatic needles. Nat. Mater. 16, 147\u2013152. https:\/\/doi.org\/10.1038\/nmat4758 (2017).","journal-title":"Nat. Mater."},{"key":"96561_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1163\/156856209x416980","volume":"21","author":"JY Lai","year":"2010","unstructured":"Lai, J. Y. et al. Ocular biocompatibility of carbodiimide cross-linked hyaluronic acid hydrogels for cell sheet delivery carriers. J. Biomater. Sci. Polym. Ed. 21, 359\u2013376. https:\/\/doi.org\/10.1163\/156856209x416980 (2010).","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"96561_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.msec.2016.11.067","volume":"72","author":"JY Lai","year":"2017","unstructured":"Lai, J. Y. & Ma, D. H. Ocular biocompatibility of gelatin microcarriers functionalized with oxidized hyaluronic acid. Mater. Sci. Eng. C Mater. Biol. Appl. 72, 150\u2013159. https:\/\/doi.org\/10.1016\/j.msec.2016.11.067 (2017).","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"96561_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/IAE.0b013e31816b3180","volume":"28","author":"JJ de Caro","year":"2008","unstructured":"de Caro, J. J. et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina 28, 877\u2013883. https:\/\/doi.org\/10.1097\/IAE.0b013e31816b3180 (2008).","journal-title":"Retina"},{"key":"96561_CR22","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.ophtha.2010.02.030","volume":"117","author":"JM Moss","year":"2010","unstructured":"Moss, J. M., Sanislo, S. R. & Ta, C. N. Antibiotic susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections. Ophthalmology 117, 2141\u20132145. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.030 (2010).","journal-title":"Ophthalmology"},{"key":"96561_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/08820538.2011.588648","volume":"26","author":"M Usman Saeed","year":"2011","unstructured":"Usman Saeed, M., Batra, R., Qureshi, F. & Clark, D. Reflux of drug during intra-vitreal anti-VEGF therapies. Semin. Ophthalmol. 26, 357\u2013360. https:\/\/doi.org\/10.3109\/08820538.2011.588648 (2011).","journal-title":"Semin. Ophthalmol."},{"key":"96561_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/archophthalmol.2010.139","volume":"128","author":"RT Cortez","year":"2010","unstructured":"Cortez, R. T., Ramirez, G., Collet, L., Thakuria, P. & Giuliari, G. P. Intravitreous bevacizumab injection: An experimental study in New Zealand white rabbits. Arch. Ophthalmol. 128, 884\u2013887. https:\/\/doi.org\/10.1001\/archophthalmol.2010.139 (2010).","journal-title":"Arch. Ophthalmol."},{"key":"96561_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S. & Singh, R. J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114, 855\u2013859. https:\/\/doi.org\/10.1016\/j.ophtha.2007.01.017 (2007).","journal-title":"Ophthalmology"},{"key":"96561_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/s0021-5155(03)00141-2","volume":"47","author":"H Sakamoto","year":"2003","unstructured":"Sakamoto, H. et al. Interleukin-8 expressed in the granulocytes of the eye in a patient with Beh\u00e7et\u2019s disease complicated by lens-induced endophthalmitis. Jpn. J. Ophthalmol. 47, 548\u2013550. https:\/\/doi.org\/10.1016\/s0021-5155(03)00141-2 (2003).","journal-title":"Jpn. J. Ophthalmol."},{"key":"96561_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205292","volume":"13","author":"D Deshmukh","year":"2018","unstructured":"Deshmukh, D. et al. Elevated cytokine levels in vitreous as biomarkers of disease severity in infectious endophthalmitis. PLoS ONE 13, e0205292. https:\/\/doi.org\/10.1371\/journal.pone.0205292 (2018).","journal-title":"PLoS ONE"},{"key":"96561_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejpb.2016.11.035","volume":"113","author":"M Guter","year":"2017","unstructured":"Guter, M. & Breunig, M. Hyaluronan as a promising excipient for ocular drug delivery. Eur. J. Pharm. Biopharm. 113, 34\u201349. https:\/\/doi.org\/10.1016\/j.ejpb.2016.11.035 (2017).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"96561_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejpb.2017.12.019","volume":"124","author":"R Egbu","year":"2018","unstructured":"Egbu, R., Brocchini, S., Khaw, P. T. & Awwad, S. Antibody loaded collapsible hyaluronic acid hydrogels for intraocular delivery. Eur. J. Pharm. Biopharm. 124, 95\u2013103. https:\/\/doi.org\/10.1016\/j.ejpb.2017.12.019 (2018).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"96561_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/jop.2010.0082","volume":"27","author":"EB Rodrigues","year":"2011","unstructured":"Rodrigues, E. B. et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J. Ocul. Pharmacol. Ther. 27, 197\u2013203. https:\/\/doi.org\/10.1089\/jop.2010.0082 (2011).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"96561_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/eye.2013.250","volume":"28","author":"MD Al Bdour","year":"2014","unstructured":"Al Bdour, M. D. & Ali, Z. R. Intravitreal foreign body following intravitreal anti-VEGF injection: A case report. Eye 28, 244\u2013245. https:\/\/doi.org\/10.1038\/eye.2013.250 (2014).","journal-title":"Eye"},{"key":"96561_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/archophthalmol.2011.367","volume":"130","author":"J Cassar","year":"2012","unstructured":"Cassar, J., Smith, T. & Kwan, T. Intravitreal inoculation of cotton after bevacizumab (Avastin) injection. Arch. Ophthalmol. 130, 126\u2013126 (2012).","journal-title":"Arch. Ophthalmol."},{"key":"96561_CR33","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.eye.6702514","volume":"21","author":"JS Pulido","year":"2007","unstructured":"Pulido, J. S., Pulido, C. M., Bakri, S. J., McCannel, C. A. & Cameron, J. D. The use of 31-gauge needles and syringes for intraocular injections. Eye (Lond) 21, 829\u2013830. https:\/\/doi.org\/10.1038\/sj.eye.6702514 (2007).","journal-title":"Eye (Lond)"},{"key":"96561_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/iae.0000000000000039","volume":"34","author":"QV Hoang","year":"2014","unstructured":"Hoang, Q. V., Jung, J. J., Mrejen, S. & Freund, K. B. Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy. Retina 34, 519\u2013524. https:\/\/doi.org\/10.1097\/iae.0000000000000039 (2014).","journal-title":"Retina"},{"key":"96561_CR35","first-page":"91","volume":"17","author":"BC Joondeph","year":"1986","unstructured":"Joondeph, B. C. & Joondeph, H. C. Purulent anterior segment endophthalmitis following paracentesis. Ophthalm. Surg. 17, 91\u201393 (1986).","journal-title":"Ophthalm. Surg."},{"key":"96561_CR36","first-page":"93","volume":"51","author":"N \u0110ogatovi\u0107","year":"2020","unstructured":"\u0110ogatovi\u0107, N. et al. Influence of vitreal reflux on intraocular pressure after intravitreal application of bevacizumab. Scr. Med. 51, 93\u201396 (2020).","journal-title":"Scr. Med."},{"key":"96561_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12886-016-0255-8","volume":"16","author":"JW Lee","year":"2016","unstructured":"Lee, J. W. et al. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol. 16, 69. https:\/\/doi.org\/10.1186\/s12886-016-0255-8 (2016).","journal-title":"BMC Ophthalmol."},{"key":"96561_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jtos.2015.12.003","volume":"14","author":"Y Eom","year":"2016","unstructured":"Eom, Y. et al. Effect of titanium dioxide nanoparticle exposure on the ocular surface: An animal study. Ocul. Surf. 14, 224\u2013232. https:\/\/doi.org\/10.1016\/j.jtos.2015.12.003 (2016).","journal-title":"Ocul. Surf."},{"key":"96561_CR39","unstructured":"ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Available at: https:\/\/www.arvo.org\/About\/policies\/statement-for-the-use-of-animals-in-ophthalmic-and-vision-research. Accessed May 2, 2020."},{"key":"96561_CR40","unstructured":"The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments). Available at: https:\/\/arriveguidelines.org. Accessed March 24, 2021."},{"key":"96561_CR41","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1167\/iovs.14-15051","volume":"55","author":"Y Eom","year":"2014","unstructured":"Eom, Y. et al. Comparison of aqueous levels of inflammatory mediators between toxic anterior segment syndrome and endotoxin-induced uveitis animal models. Invest. Ophthalmol. Vis. Sci. 55, 6704\u20136710. https:\/\/doi.org\/10.1167\/iovs.14-15051 (2014).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"96561_CR42","doi-asserted-by":"publisher","DOI":"10.3791\/53878","author":"SJ Ahn","year":"2016","unstructured":"Ahn, S. J. et al. Use of rabbit eyes in pharmacokinetic studies of intraocular drugs. J. Vis. Exp. JoVE https:\/\/doi.org\/10.3791\/53878 (2016).","journal-title":"J. Vis. Exp. JoVE"},{"key":"96561_CR43","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.1167\/iovs.12-10164","volume":"53","author":"M Kakinoki","year":"2012","unstructured":"Kakinoki, M. et al. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest. Ophthalmol. Vis. Sci. 53, 5877\u20135880. https:\/\/doi.org\/10.1167\/iovs.12-10164 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"96561_CR44","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","volume":"115","author":"Q Zhu","year":"2008","unstructured":"Zhu, Q. et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115, 1750\u20131755. https:\/\/doi.org\/10.1016\/j.ophtha.2008.04.023 (2008).","journal-title":"Ophthalmology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96561-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96561-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96561-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:54:38Z","timestamp":1670072078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96561-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["96561"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-96561-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16996"}}